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When sadness overwhelms
Every child experiences bouts of sadness from time to time. For most children, these bouts are transient 
and do not interfere with development and 
well-being. Yet for some young people, their 
low mood becomes prolonged and impedes 
their ability to thrive. In these situations, 
a thorough clinical assessment can help 
families and health practitioners figure out 
what steps to take next. 
Determining if a diagnosis  
is warranted
When a practitioner conducts a mental 
health assessment, often as part of a 
multidisciplinary team, they typically 
begin by interviewing the child and the caregiver. The practitioner will commonly ask 
questions about the onset, frequency, severity and impact of symptoms — which may 
affect mood, activities, sleep, eating and energy levels. If a child is experiencing multiple 
depressive symptoms that impair their functioning, the practitioner must also ascertain 
that the problems are not due to another mental disorder, such as anxiety, or due to adverse 
circumstances, such as parenting problems or even child maltreatment. (Whenever there 
are any questions or concerns about possible child maltreatment, the appropriate child 
protection agency must be contacted.) Table 1 describes the full criteria for diagnosing 
depression (known as major depressive disorder), as set out in the Diagnostic and Statistical 
Manual of Mental Disorders.1
o v e r v i e w
According to updated 
global burden-of-
disease data, major 
depressive disorder 
is among the top 
five leading causes 
of years-lived-with-
disability worldwide.
For depression, as with many mental disorders, the most effective way to help 
children is to prevent this condition from ever occurring.
Table 1: Diagnostic Criteria for Major Depressive Disorder1  
Major depressive disorder occurs when a child experiences at least five of the symptoms listed 
below during the same two-week period. these symptoms must include either a depressed or 
irritable mood or loss of interests or pleasures. Beyond causing distress, symptoms must also 
result in impaired functioning at home, at school or in the community. 
•	 Depressed	or	irritable	mood	most	of	the	day,	nearly	every	day
•	 Greatly	reduced	interests	or	pleasures	affecting	almost	all	activities,	nearly	every	day
•	 Significant	changes	in	weight	or	appetite		
•	 Sleep	disturbances	most	nights
•	 Significant	changes	in	activity	levels	most	days
•	 Tiredness	or	loss	of	energy	most	of	the	time
•	 Feelings	of	worthlessness	or	excessive	guilt	nearly	every	day
•	 Reduced	ability	to	concentrate	most	days
•	 Recurrent	thoughts	of	death	or	suicide
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What puts children at risk for depression?
Although researchers have yet to determine the causes of depression, they have been able to identify a 
number of important risk factors. We present the factors that have been established using strong research 
methodology — namely, surveys following large groups of children who were representative of the 
populations they were drawn from. While such studies cannot prove causation, they can nevertheless identify 
factors that clearly precede depression in children and that may be amenable to interventions. 
We identified four such surveys. One included more than 100,000 American youth and found that being 
female was a risk factor for depression.2 In fact, girls were approximately three times more likely than boys 
to develop depression.2 A second survey, of more than 2,700 American youth, identified several other risk 
factors for depression.3 These included parents having depression or antisocial behaviour and children having 
frequent negative moods, impulsivity or behaviour problems at age 11.3 While these five factors increased 
the likelihood of being diagnosed with depression by age 17, the strongest predictor 
was nevertheless a sixth factor: a history of child maltreatment. In fact, children who 
experienced physical abuse had a tenfold increase in their odds of later being diagnosed 
with depression compared to children without this history.3
A third survey, in New Zealand, followed 945 children from age three to 32.4 The 
risk factors identified by the researchers included a family history of depression and child 
behaviour problems between ages five and 11.4
A fourth survey, of 1,715 Canadian children, confirmed many of the same risk factors.5 
When children were between ages four and eight, having anxiety and depressive symptoms 
predicted later depression, but only for boys, while having a depressed caregiver or losing a biological parent 
predicted later depression, but only for girls.5 In contrast, when children were between ages 10 and 14, having 
anxiety and depressive symptoms increased the likelihood for both boys and girls going on to experience 
depression in their later teen years. Yet some other risk factors for these older children did vary by gender. Low 
self-esteem predicted later depression for adolescent boys, while behaviour problems predicted later depression 
for girls. Age, however, was a consistent factor overall, with both boys and girls showing more depressive 
symptoms as they became older.
Interplay between genes and environment 
Across these four surveys, adverse childhood experiences were found to be risk factors for depression, 
including parental depression and child maltreatment. Ideally, no child should be exposed to these kinds of 
adversities. Still, not all children who have these experiences go on to develop depression. To help identify 
which children are particularly vulnerable, and to help inform interventions, researchers have examined the 
interplay between genetics and adverse experiences. We report on two studies that have investigated this 
interplay and its impact on the development of depression.
One study on gene-environment interplay included nearly 500 American children, roughly half of whom 
had experienced maltreatment. This included neglect (79%), emotional abuse (67%), physical abuse (32%) 
and/or sexual abuse (8%), with most children having been exposed to multiple types of maltreatment.6 The 
researchers demonstrated that depressive symptoms were more likely following child maltreatment when 
specific interactions between gene systems associated with cortisol regulation and stress sensitivity occurred. 
They concluded that the impact of a chronic stressor such as child maltreatment was indeed moderated by 
genetic variation.6
ov e r v i e w
Adverse childhood 
experiences were 
found to be risk 
factors for depression, 
including parental 
depression and child 
maltreatment.   
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The importance of gene-environment interplay was similarly shown in the survey mentioned previously 
that followed children from New Zealand.7 Researchers examined stressful life events and genetic profiles in 
a subsample of 847 participants. They found that child maltreatment — as well as financial, housing, health 
or relationship concerns in early adulthood — predicted depression diagnoses at age 25, but only among 
individuals with specific genetic profiles affecting stress sensitivity.7 These researchers concluded that negative 
life events can influence gene expression, contributing to mental health symptoms later in life.
Research continues on gene-environment interactions and on the implications for helping children — 
and the adults they will become. This research does not tell the whole story for a condition like depression 
that has multiple causes. But these studies nevertheless highlight the importance of understanding individual 
differences in genetic vulnerability. Even more importantly, however, they underscore the importance of 
intervening early to prevent harmful events such as child maltreatment that can play a role in depression.6, 8
Intervening to reduce risk 
For depression, as with many mental disorders, the most effective way to help children 
is to prevent this condition from ever occurring. Even though the causes of depression 
have yet to be fully determined, we know enough about modifiable risk factors to take 
action now. We can prevent many cases of child maltreatment. Our Spring 2009 issue 
identified programs that can effectively reduce this important risk factor, such as nurse 
home visitation. (This program is now known as Nurse-Family Partnership.) We can also 
implement effective depression prevention programs in childhood, including for children 
whose parents are depressed, as outlined in our Summer 2017 issue. 
Beyond the fundamental issue of ensuring positive childhood experiences, depressive disorders have 
collective importance for another reason. According to updated global burden-of-disease data, major 
depressive disorder is among the top five leading causes of years-lived-with-disability worldwide.9 To reduce 
this burden for individuals and for societies, it is crucial not only to prevent depression in childhood, but also 
to treat depression effectively when it usually first occurs — in childhood. Our Summer 2017 issue covered 
the prevention options. The Review article that follows identifies the treatment options.
It is crucial not only 
to prevent depression 
in childhood, but also 
to treat depression 
effectively when it 
usually first occurs — 
in childhood.
ov e r v i e w
Even though the causes of depression have yet to be fully determined, we know enough about modifiable risk factors to 
take action now.
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Effective treatments  
for childhood depression
Children and adolescents who develop depression need timely and effective 
treatments. To ensure good care for 
these young people, practitioners 
and policy-makers in turn need 
credible information on treatments 
that work. To meet these needs, this 
review set out to identify the most 
effective treatments for childhood 
depression. 
We conducted a 20-year search 
for randomized controlled trials 
(RCTs) evaluating childhood 
depression treatments. Quality 
assessment was built into our 
inclusion criteria to ensure we 
reported on the best available evidence. (For more information, 
please see our Methods.) We retrieved and assessed 99 RCTs, 
14 of which met our inclusion criteria. The 14 trials comprised 
four RCTs evaluating cognitive-behavioural therapy (CBT), nine 
evaluating medications, and one evaluating CBT and the medication 
fluoxetine — both independently and combined. (Because we covered 
this latter RCT in our Spring 2008 issue, we provide only the main 
highlights in the sidebar on page 11.)
The ABCs of the CBT trials
All four CBT programs — Individual CBT, SPARX, and two separate 
trials of Coping with Depression — provided participating children 
with core CBT components. These components were education 
on the CBT model, encouragement to engage in pleasant or fun 
activities, and instruction and practice in challenging inaccurate 
thinking (i.e., cognitive restructuring). All four programs also taught 
children techniques for improving relationships, ranging from 
interpersonal skills to social problem-solving techniques to conflict resolution strategies. Still, the programs 
varied: in format, with individual (Individual CBT), group (Coping with Depression) and self-delivery (SPARX) 
options; and in the number of sessions or modules (which ranged from seven to 16).
All four RCTs compared CBT to another intervention. Individual CBT was compared to a brief supportive 
intervention in the United Kingdom. This comparison condition involved children providing information 
about their mental health symptoms, their school and family life, and their engagement in social activities.11
r e v i e w
All four CBT evaluations showed benefits for children with depression, including 
substantially lowered rates of diagnoses and symptoms.
What about interpersonal 
psychotherapy?
some readers may be surprised that no rCts assessing interpersonal therapy 
(iPt) were included in our review, particularly 
given that iPt was identified as reducing 
depressive symptoms in children and youth 
in our 2014 report Child and Youth Mental 
Disorders: Prevalence and Evidence-Based 
Interventions.10 although we did assess six 
rCts of iPt for our current review, none met 
inclusion criteria due to methods concerns — 
mainly a lack of follow-up. this suggests that 
although there is evidence supporting iPt, this 
evidence is not as robust as for CBt. When 
practitioners choose to use iPt, they should 
therefore pay particularly close attention to 
ensuring that child outcomes are positive.
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SPARX, a self-delivered computer program, was compared to typical treatment services available to youth 
in New Zealand. While most comparison youth received counselling at clinics or in schools (the type of 
counselling was not reported), 13% were put on waitlists and received no treatment.12 A very small number 
(2%) were also prescribed medication (the type was not reported).12 As well, this RCT was specifically 
designed to assess whether SPARX was “not inferior” to usual treatment (rather than 
assessing whether it was superior).
Coping with Depression I, meanwhile, was compared to life skills training in the United 
States. This comparison program focused on preparing youth for adulthood, including 
activities such as completing job applications and renting an apartment, and also provided 
tutoring.13 In contrast, Coping with Depression II was compared to typical treatment 
services available at a health maintenance organization in the US. These services included 
outpatient mental health specialty care visits, inpatient services and medications. (These 
services were also available to youth randomized to Coping with Depression II; in other 
words, intervention children received the CBT program plus usual services.)14 Table 2 gives more information 
on these four CBT programs and their evaluations.
r e v i e w
Keeping CBT research relevant
Researchers for these four RCTs also paid careful attention to who was included in the studies. In particular, 
because SPARX was self-administered, youth were excluded if they were at high risk for self-harm or suicide, 
or if their depression was assessed as being too severe for a self-help resource.12 
The three other CBT RCTs, meanwhile, tested effectiveness in populations typically seen in clinical 
practice. In addition to all young people meeting criteria for depression (or dysthymia for Coping with 
Depression II), most participants had concurrent mental disorders. In Individual CBT, 65% of young people 
also met criteria for oppositional defiant, conduct or anxiety disorders.15 In Coping with Depression I, which 
recruited from juvenile justice settings, all youth met diagnostic criteria for both depression and conduct 
 
Table 2: Cognitive-Behavioural Therapy (CBT) Evaluations
Child ages 
(Country)
8 –17 years 
(United 
Kingdom)
12 –19 years
(new Zealand)
 
13 –17 years
(United states)
 
13 –18 years
(United states)
Sample  
size
31
 
30
 
94
 
93
 
45
 
48
 
41
 
47
 
Intervention  
Comparison
Individual CBT 15
 
Brief supportive 
intervention
SPARX 12
 
treatment as usual 
Coping with 
Depression I 13
life skills training
 
Coping with 
Depression II 14
treatment as usual 
Delivery format
 
9 individual CBt sessions delivered in community settings over 
6 months
9 individual sessions reviewing well-being + social activities 
delivered in community settings over 6 months
7 computerized CBt modules individually completed over  
4–7 weeks 
Youth could access regularly available treatment services at 
community clinics + schools
16 group CBt sessions delivered in community settings over  
8 weeks + 2 optional parent information sessions
16 group sessions focused on life skills + tutoring delivered in 
community settings over 8 weeks
16 group CBt sessions delivered in community settings over  
8 weeks + 3 parent information sessions 
Youth could access regularly available treatment services at 
community clinics + hospitals 
 
All children with 
depression should 
have ready access 
to CBT — through 
publicly provided 
children’s mental 
health services.
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disorder.13 As well, 72% had one or more substance use disorders and 40% had a history of attempting 
suicide.13 In Coping with Depression II, participating young people had an average of 1.9 diagnoses, and all had 
a parent with a mood disorder.14
Medication trials: What’s being prescribed?
The nine medication RCTs that met our inclusion criteria 
evaluated six different drugs. Four medications — amitriptyline, 
clomipramine, desipramine and escitalopram — were each 
evaluated in a single RCT. In contrast, fluoxetine was evaluated 
in five separate RCTs, and duloxetine was evaluated in two 
separate RCTs (with one evaluating two different doses of this 
medication). All medications were compared to a placebo. As well, 
all medications were provided orally, except clomipramine, which 
was provided intravenously in a single dosage. 
Seven RCTs were conducted exclusively in the US. The 
remaining two RCTs were conducted in multiple countries 
(including Canada in one case). Participants in one fluoxetine 
evaluation (fluoxetine V) stood out because beyond having 
depression, they also all met diagnostic criteria for a current substance use disorder as well as current or past 
conduct disorder.16 So all adolescents in this study also received CBT to address their substance use issues, 
regardless of whether they received fluoxetine or placebo.16 Table 3 gives more information on all nine 
medication RCTs. 
r e v i e w
A drug by any other name
the medications listed in this article are sold in Canada under various 
brand names, summarized in the 
table below.
Antidepressant Medications 25 
Generic name Brand name
amitriptyline  elavil
Clomipramine anafranil
desipramine not applicable
duloxetine Cymbalta
escitalopram Cipralex
Fluoxetine Prozac
 
Table 3: Medication Evaluations
Child ages (Country)
12 –18 years (Us)
14 –18 years (Us)
13 –17 years (Us)
6 –17 years (Us)
7 –17 years (9 countries)
 
7 –17 years (4 countries)
 
7 –17 years (Us)
8 –17 years (Us)
13 –19 years (Us) 
Sample size*
27
16
45
268
337
 
463
 
96
219
126 
Medication 
Amitriptyline 17
Clomipramine 18
Desipramine 19
Escitalopram 20
Duloxetine I 21
Fluoxetine I 21
Duloxetine II 22
Fluoxetine II 22
Fluoxetine III 23
Fluoxetine IV 24
Fluoxetine V 16
Dosage + duration
300 mg maximum daily dose taken over 10 weeks
200 mg single intravenous dose taken over 3 hours
300 mg maximum daily dose taken over 6 weeks
20 mg maximum daily dose taken over 8 weeks
120 mg maximum daily dose taken over 10 weeks
40 mg maximum daily dose taken over 10 weeks
30 or 60 mg fixed daily dose taken over 10 weeks
20 mg fixed daily dose taken over 10 weeks
20 mg fixed daily dose taken over 8 weeks
20 mg fixed daily dose taken over 9 weeks
20 mg fixed daily dose taken over 16 weeks  
* sample size includes children receiving both medication(s) and placebo.
 
 
How well did the CBT programs work?
Individual CBT and Coping with Depression I and II all assessed depression diagnoses at final follow-up, one to 
two years after the interventions ended. According to this outcome indicator, most children participating in 
CBT no longer had depression — despite 100% meeting criteria for this diagnosis (or dysthymia for Coping 
with Depression II) at study outset. After-treatment diagnosis rates ranged from only 10.5% for Coping with 
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Depression II to 36.6% for Coping with Depression I.13–14, 26 However, these differences in diagnosis rates were 
not statistically significant in the three studies.13–14, 26 (The SPARX RCT did not assess diagnoses.)
Beyond diagnoses, these three CBT programs also substantially reduced depression symptoms at final 
follow-up — by child, parent and clinician ratings. Children participating in Individual CBT and Coping 
with Depression I and II experienced symptom reductions of greater than 50% on at least one measure.13–14, 26 
Coping with Depression II had particularly varied rates of symptom reductions because parent-rated symptoms 
were relatively low compared to child-rated symptoms at baseline. Still, similar to the diagnostic findings, 
these three studies found no significant difference between CBT and the comparison interventions.13–14, 26
 Meanwhile, teens participating in SPARX experienced slightly greater symptom reductions than teens 
receiving treatment as usual, when assessed at three-month follow-up. Since this was a “non-inferiority trial,” 
rather than assessing whether SPARX was superior to treatment as usual, it assessed and confirmed that SPARX 
was as beneficial as typical treatments offered in the community.12 Table 4 summarizes the findings from the 
four CBT studies, including diagnosis and symptom reductions at final follow-up. 
r e v i e w
 
Table 4: Cognitive-Behavioural Therapy (CBT) Outcomes at Final Follow-Up*
Symptom reductions
49.4 – 53.9%
56.6 – 60.6%
32.7% 
30.2% 
40.4 – 60.6% 
51.3 – 70.3% 
12.5 – 65.8% 
14.0 – 61.4% 
Diagnostic rates 
25.9%
14.8%
not assessed 
36.6%
37.0%
10.5%
7.7% 
Intervention  
Comparison
Individual CBT  26
Brief supportive intervention
SPARX  12
treatment as usual
Coping with Depression I  13
life skills training
Coping With Depression II  14
treatment as usual 
Follow-up
2 years 
3 months
 
1 year
 
2 years
  
* none of the differences between intervention and comparison groups were statistically significant. 
How well did the medications work?
For the six medications, effects were assessed for the duration of the nine RCTs, which ranged from 
six days (for intravenous clomipramine) to 16 weeks (for oral fluoxetine V), but long-term follow-up was 
not conducted for any medications.16–24 Diagnostic outcomes were only assessed for amitriptyline and 
desipramine.17, 19 Neither medication significantly outperformed the placebo on this important outcome 
indicator. Three of the six medications — amitriptyline, desipramine and duloxetine — 
also failed to outperform placebo on any symptom measures.17, 19, 21–22
In comparison, clomipramine, escitalopram and fluoxetine resulted in significant 
symptom reductions compared to placebo on at least one measure.16, 18, 19, 23–24 The 
clomipramine RCT found reductions on two of three symptom measures, while the 
escitalopram RCT found reductions on one of three symptom measures.18, 20
Meanwhile, results varied across the five fluoxetine trials. In two RCTs (fluoxetine I 
and II), the medication failed to outperform placebo on either of the two symptom 
measures.21–22 However, the three other RCTs (fluoxetine III through V) did show significant benefits on one 
to four symptom measures.16, 23–24 Two of the successful fluoxetine RCTs also assessed the clinical importance 
of the symptom reductions. In fluoxetine IV, effect sizes were medium for two outcomes (Cohen’s d = 0.51 and 
If medication  
is being considered 
as part of a child’s 
treatment plan, 
fluoxetine should be 
the first choice.
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0.54) and small for one (Cohen’s d = 0.31), while in fluoxetine V, the effect size was large for one outcome 
(Hedges’ g = 0.78).16, 24 Table 5 summarizes the findings from all the medication evaluations.
 
Table 5: Medication Outcomes at Post-Test
No significant difference over placebo
diagnosis + symptoms (4 of 4)
symptoms (1 of 3)
diagnosis + symptoms (4 of 4)
symptoms (2 of 3)
symptoms (2 of 2)
symptoms (2 of 2)
symptoms (2 of 2)
symptoms (2 of 2)
symptoms (2 of 4)
symptoms (1 of 5)
symptoms (1 of 2)
Medication 
Amitriptyline 17
Clomipramine 18
Desipramine 19
Escitalopram 20
Duloxetine I 21
Fluoxetine I 21
Duloxetine II 22
Fluoxetine II 22
Fluoxetine III 23
Fluoxetine IV 24
Fluoxetine V 16
Favouring medication 
none
  symptoms (2 of 3)
none
  symptoms (1 of 3)
none
none
none
none
  symptoms (2 of 4)
  symptoms (4 of 5)
  symptoms (1 of 2) 
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Side effects can be substantial
All six medications led to side effects for children, including the three medications that reduced depressive 
symptoms (clomipramine, escitalopram and fluoxetine). With clomipramine, 25% experienced dizziness, 
25% experienced sedation and 13% experienced nausea.18 (The authors did not report whether these rates 
significantly differed from placebo.)18
With escitalopram, 23% experienced headaches and 11% experienced abdominal pain (although rates for 
both side effects were similar for placebo).20 For escitalopram, two serious adverse events were also reported 
(pneumonia and an accidental injury), and 2% of children discontinued the study due to side effects.20
With fluoxetine, reporting of side effects varied across the five RCTs. With fluoxetine I, 5% of children 
experienced side effects serious enough to require hospitalization, including gastritis and lymphadenitis.21 
As well, one child discontinued the study after a suicide attempt.21 With fluoxetine II, 5% of children 
also experienced side effects serious enough to require hospitalization, including aggression, somnolence, 
destructive behaviour and intentional overdose.22 With fluoxetine III, 8% of children discontinued the study 
due to side effects, which included manic symptoms and severe rash.23 With fluoxetine IV, 5% of children 
discontinued the study due to side effects, which included manic symptoms, rash and agitation.24 As well, 
in this trial, significantly more children on fluoxetine reported headaches compared to those on placebo.24 
Finally, with fluoxetine V, 6% of adolescents were evaluated in an emergency room or were hospitalized due to 
increased suicidality during the study.16
Making sense of the findings
All four CBT evaluations showed benefits for children with depression, including substantially lowered rates 
of diagnoses and symptoms. In fact, rates of depression diagnoses dropped by 74% for Individual CBT and 
by 63% for Coping with Depression I. Still, paradoxically, these differences were not statistically significant — 
probably because comparison children also had large diagnostic reductions. One possible explanation for this 
result is that the comparison interventions likely offered some therapeutic benefit. In fact, two of the four 
comparison conditions comprised usual treatment services in the community. So some comparison children 
may also have received CBT, boosting their outcomes.
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Another explanation is that many children failed to complete the CBT programs. For example, with 
Individual CBT, only 50% of participants completed all the sessions and only 50% attended the sessions 
on cognitive restructuring, a core component of CBT.11 Similarly, with Coping with Depression I, children 
attended only eight of 16 sessions on average.13 Compliance was also a concern with Coping with Depression II; 
youth attended only 10 of 16 sessions, on average, and completed homework for only 35% of sessions they 
attended, on average.14 Finally, with SPARX, 40% of youth did not complete all seven program modules and 
38% failed to complete most or all of the homework.12 On balance, therefore, children may not have received 
adequate “doses” of CBT in these trials — a situation that may mirror typical clinical practice.
Two of the five fluoxetine RCTs also did not find benefits for this medication. Compared to the three 
trials with positive findings, these two used the same or higher doses, for similar time periods, and in children 
of similar ages.16, 21–24 However, three of five fluoxetine studies did result in youth experiencing significant 
symptom improvement.
Recapping the results
This 20-year review of childhood depression treatments found 
that three CBT programs — Individual CBT, SPARX and Coping 
with Depression — reduced diagnoses and symptoms from three to 
24 months after the programs ended. (Similarly, our previous review 
showed that a 15-session CBT program reduced depression symptoms 
for the majority of adolescents.27 Please see the sidebar for more 
information on this earlier review.) Still, the three CBT programs 
did not show statistically significant benefits over the comparison 
interventions — perhaps because the comparison interventions were 
also likely quite robust, and perhaps because many children did not 
complete their full course of CBT (which is common with childhood 
mental health treatments in general).28 Nevertheless, among the 
psychosocial treatments, CBT still has the strongest evidence 
supporting its use.
This review also found that the medication fluoxetine led to 
significant improvements for young people in three of five RCTs. (These outcomes build on our previous 
review of a fluoxetine study, also highlighted in the sidebar, showing that depression symptoms improved 
for the majority of adolescents on the medication.) Our current review also found evidence supporting the 
use of the medications clomipramine and escitalopram, according to one RCT each. Notably, fluoxetine, 
clomipramine and escitalopram were all associated with side effects. Meanwhile, we found no evidence 
supporting the use of the medications amitriptyline, desipramine or duloxetine for childhood depression.
Implications for practice and policy 
Our findings suggest the following six implications for practitioners and policy-makers:
•	 Make	CBT	available	to	all	children	with	depression. Strong evidence still supports CBT for 
treating childhood depression. It is the best among the psychosocial interventions, and it comes with 
no side effects. Consequently, all children with depression should have ready access to CBT — through 
publicly provided children’s mental health services, to ensure that families do not have to incur the costs 
for essential treatments. To facilitate this, children’s mental health services need to train and support 
practitioners to provide CBT. Such training and support initially occurred in BC through the first Child 
and Youth Mental Health Plan (2003–08).32 These efforts need to be supported and maintained.
Revisiting a noteworthy study 
We devoted an article in our spring 2008 issue to the treatment for adolescents 
with depression study. this randomized 
controlled trial examined whether combining 
CBt and fluoxetine would provide better 
outcomes than either treatment alone. the 
authors found that combining CBt and 
fluoxetine was significantly more effective 
than CBt alone, but not fluoxetine alone, in 
reducing depression diagnoses after 12 weeks 
of treatment.29–30 however, after 36 weeks 
of treatment, no significant differences in 
depression symptoms were reported among 
the three treatments — fluoxetine alone, CBt 
alone, or the two combined — according to 
either child or clinician ratings.31 (diagnoses 
were not assessed at 36 weeks.) 
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•	 Practise	in	ways	that	encourage	children	to	complete	the	treatment.	Young people often stop 
before completing a full course of CBT, according to the studies we reviewed. So practitioners must 
find ways to engage and retain young people. Strategies can include offering flexible appointment times, 
finding innovative ways to teach CBT skills, and ensuring that materials are adapted to the individual’s 
learning needs and cultural setting. (Please see the final sidebar for more information on ways to encourage 
young people’s participation.)
•	 Consider	self-directed	CBT	for	lower-risk	youth. For adolescents with milder depression who are 
not at risk for suicide, computer-based, self-administered CBT programs such as SPARX can be effective. 
These programs can also reach greater numbers of young people than more traditional individual- or 
group-delivered approaches. However, careful monitoring is warranted when using this approach. As with 
other forms of CBT, self-administered programs are best provided through publicly funded children’s 
mental health services so cost is not a deterrent. Public provision can also ensure appropriate oversight 
(e.g., monitoring to ensure that young people do not require more intensive, practitioner-delivered 
interventions).
•	 Use	the	most	effective	medications. Of the current medication choices, the evidence is most robust 
for fluoxetine in treating childhood depression. Therefore, if medication is being considered as part of a 
child’s treatment plan, fluoxetine should be the first choice. 
•	 If	medication	is	prescribed,	monitor	outcomes	and	side	effects	frequently	and	
comprehensively. Young people who are prescribed fluoxetine are at risk for experiencing side effects. 
Although rare, serious events such as suicidal thoughts can occur. As a result, anyone prescribed this 
medication needs regular monitoring for both benefits and side effects.
•	 When	medication	is	prescribed,	also	offer	children	CBT. Many children and adolescents experience 
great benefit from taking an antidepressant. Still, the available evidence on fluoxetine is almost exclusively 
based on short-term use. CBT should therefore also be provided because it has more enduring benefits, 
equipping children and youth to cope long after medications are finished.
All young people with depression need timely access to effective treatments, including psychosocial 
interventions such as CBT and medications such as fluoxetine. These treatments can reduce distress and 
disability in the short term. They can also reduce future distress and disability, particularly if enduring 
treatments such as CBT are offered — giving children coping skills for life.  
Keep them coming back
Young people commonly drop out of treatment early,28 so practitioners need strategies to address this issue. Fortunately, several approaches can help when using cognitive-
behavioural therapy (CBt) for depression. First, let young people know why it is worth their 
time to keep coming back. Practitioners can do this by educating children and youth about 
the benefits of CBt, including its success rates. Second, give young people and their parents 
or caregivers an overview of what CBt entails and why. educate them about the CBt model 
and the need to apply their new skills on a daily basis for maximum benefit. Caregivers, in 
particular, can offer crucial day-to-day supports to help young people stick with the program. 
Third, give children choices. For example, young people can select the ordering of core CBt 
components, including whether they want to begin with increasing activities that bring them 
pleasure or challenging inaccurate thinking. Fourth, make CBt culturally relevant. For example, 
children can be encouraged to identify and engage in traditional cultural practices that bring 
them satisfaction. in this way, CBt can be made applicable to any culture. Fifth, track young 
people’s symptoms using a rating scale at every session, giving concrete feedback on how 
the hard work is paying off. Finally, ask for feedback after every session, including what went 
well and what was challenging. taken together, these strategies can help to ensure that when 
young people walk out the door, they will be certain to return.
For more information on 
our research methods, 
please contact
Jen Barican
chpc_quarterly@sfu.ca 
Children’s Health Policy Centre 
Faculty of Health Sciences  
Simon Fraser University
Room 2435  
515 West Hastings St. 
Vancouver, BC  V6B 5K3 
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We use systematic review (SR) methods adapted from the Cochrane Collaboration and Evidence-Based Mental Health. We build quality assessment into our inclusion criteria to ensure that we report on the best available evidence, requiring that intervention studies use randomized 
controlled trial (RCT) methods and also meet additional quality indicators (as outlined in Table 7, below). 
This review involved a 20-year search for RCTs evaluating treatments for childhood depression. Table 6 
outlines our database search strategy.
To identify additional RCTs, we also hand-searched reference lists from previous Children’s Health 
Policy Centre publications. Using this approach, we identified 99 RCTs in total. Two team members then 
independently assessed each RCT, applying the inclusion criteria outlined in Table 7. 
m et h o d s
•	 Campbell,	Cochrane,	CINAHL,	ERIC,	Medline	and	PsycINFO		
•	 Depression	or	depressive	or	major	depressive	disorder	(MDD)	or	dysthymia	and 
treatment or intervention or therapy  
•	 Peer-reviewed	articles	published	in	English	between	1997	and	2017*
•	 Children	aged	18	years	or	younger
•	 Systematic	review,	meta-analysis	or	RCT	methods	used
Table 6: Search Strategy
Sources
 
Search Terms 
Limits
* a newly published article outside the search dates was also retrieved and assessed.
Fourteen RCTs met all the inclusion criteria. Data from these studies were then extracted, summarized and 
verified by two or more team members. Throughout our process, any differences between team members were 
resolved by consensus.   
Table 7: Inclusion Criteria for RCTs  
•	 Clear	descriptions	were	provided	of	participant	characteristics,	settings	and	interventions
•	 Interventions	were	evaluated	in	a	high-income	country	(according	to	World Bank standards),  
for comparability with Canadian policy and practice settings 
•	 Interventions	aimed	to	treat	childhood	depression
•	 At	study	outset,	most	participants	had	a	depression	diagnosis	
•	 Reliability	and	validity	of	all	primary	outcome	measures	or	instruments	was	documented
•	 Levels	of	statistical	significance	were	reported	for	primary	outcome	measures
•	 Studies	were	excluded	where	authors	indicated	lack	of	statistical	power	for	assessing	primary	
outcomes
Psychosocial Treatment Studies
•	 Participants	were	randomly	assigned	to	intervention	and	comparison	groups	at	study	outset
•	 Follow-up	was	three	months	or	more	(from	the	end	of	the	intervention)
•	 Attrition	rates	were	20%	or	less	at	follow-up	and/or	intention-to-treat	analysis	was	used
•	 Child	outcome	indicators	included	depression	diagnoses	and	symptoms,	assessed	at	follow-up	
using two or more informant sources (e.g., child, parent, teacher, clinician, observation)
•	 At	least	one	outcome	rater	was	blinded	to	participants’	group	assignment
Medication Studies
•	 Participants	were	randomly	assigned	to	intervention	and	placebo	groups	at	study	outset
•	 Attrition	rates	were	20%	or	less	at	post-test	and/or	intention-to-treat	analysis	was	used
•	 Child	outcome	indicators	included	depression	diagnoses	and	symptoms,	assessed	at	post-test	 
using two or more informant sources (e.g., child, parent, teacher, clinician, observation)
•	 Double-blinding	procedures	were	used
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l i n ks  to  pa st  i s s u e s
2017  /  Volume 11 
3 – Preventing childhood depression
2 – Supporting LGBTQ+ youth
1 – Helping children with ADHD 
2016  /  Volume 10 
4 – Promoting self-regulation and preventing  
ADHD symptoms 
3 – Helping children with anxiety
2 – Preventing anxiety for children
1 – Helping children with behaviour problems
2015  /  Volume 9 
4 – Promoting positive behaviour in children
3 – Intervening for young people with eating disorders
2 – Promoting healthy eating and preventing eating 
disorders in children
1 – Parenting without physical punishment
2014  /  Volume 8 
4 – Enhancing mental health in schools
3 – Kinship foster care
2 – Treating childhood obsessive-compulsive disorder
1 – Addressing parental substance misuse
2013  /  Volume 7 
4 – Troubling trends in prescribing for children
3 – Addressing acute mental health crises
2 – Re-examining attention problems in children 
1 – Promoting healthy dating relationships
2012  /  Volume 6 
4 – Intervening after intimate partner violence
3 – How can foster care help vulnerable children? 
2 – Treating anxiety disorders
1 – Preventing problematic anxiety
2011  /  Volume 5 
4 – Early child development and mental health
3 – Helping children overcome trauma
2 – Preventing prenatal alcohol exposure
1 – Nurse-Family Partnership and children’s mental health
2010  / Volume 4 
4 – Addressing parental depression
3 – Treating substance abuse in children and youth
2 – Preventing substance abuse in children and youth
1 – The mental health implications of childhood obesity
2009 / Volume 3 
4 – Preventing suicide in children and youth
3 – Understanding and treating psychosis in young people
2 – Preventing and treating child maltreatment
1 – The economics of children’s mental health
2008 / Volume 2 
4 – Addressing bullying behaviour in children 
3 – Diagnosing and treating childhood bipolar disorder
2 – Preventing and treating childhood depression
1 – Building children’s resilience
2007 / Volume 1
4 – Addressing attention problems in children
3 – Children’s emotional wellbeing
2 – Children’s behavioural wellbeing
1 – Prevention of mental disorders
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